

Form PTO-1449		Docket No. GZ 2094.00		Appl. No. 09/812,238	
INFORMATION DISCLOSURE STATEMENT		Applicant(s) Charles A. NICOLETTE			
(use several sheets if necessary)		Filing Date: March 19, 2001		Group Art Unit: Not Yet Assigned 1654	
U.S. PATENT DOCUMENTS					
Examiner Initials	Ref. No.	Date	Document No.	Name	Class Subclass Filing Date (if appropriate)
FOREIGN PATENT DOCUMENTS					
Examiner Initials	Ref. No.	Date	Document No.	Name	Class Subclass Translation YES NO
ADK	1.	11/02/95	WO 95/29193	Govt. of the United States	
OTHER DOCUMENTS (including author, title, date, pertinent pages, etc.)					
Examiner Initials	Ref. No.	Title			
	2.				
	3.				

EXAMINER: <i>ADK</i>	DATE CONSIDERED: <i>8/19/04</i>
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	

Form PTO-1449	Docket No. 126881209400	Appl. No. 09/812,238
INFORMATION DISCLOSURE STATEMENT	Applicant(s) Charles A. NICOLETTE	
(use several sheets if necessary)	Filing Date: March 19, 2001	Group Art Unit: 4614 1654

## U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date (if appropriate)
ADK	1.	07/28/87	4,683,195	Mullis et al.			
ADK	2.	07/28/87	4,683,202	Mullis			
ADK	3.	06/28/88	4,754,065	Levenson et al.			
ADK	4.	01/24/89	4,800,159	Mullis et al.			
ADK	5.	08/08/95	5,440,013	Kahn			
ADK	6.	11/17/98	5,837,249	Heber-Katz et al.			

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Translation YES NO
ADK	7.	08/01/96	WO 96/23060	The Government of the United States of America			

## OTHER DOCUMENTS

(including author, title, date, pertinent pages, etc.)

Examiner Initials	Ref. No.	Title
ADK	8.	Altman, J.D. et al., "Phenotypic analysis of antigen-specific T lymphocytes" (1996) <i>Science</i> 274(5284):94-96
ADK	9.	Bertoni, R. et al., "Human class I supertypes and CTL repertoires extend to chimpanzees" (1998) <i>J. Immunol.</i> 161:4447-4455
ADK	10.	Boczkowski, D. et al., "Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo" (1996) <i>J. Exp. Med.</i> 184:465-472
ADK	11.	Bordignon, C. et al., "Retroviral vector-mediated high-efficiency expression of adenosine deaminase (ADA) in hematopoietic long-term cultures of ADA-deficient marrow cells" (1989) <i>PNAS USA</i> 86:6748-6752
ADK	12.	Carter, B.J., "Adeno-associated virus vectors" (1992) <i>Curr. Op. Biotechnol.</i> 3:533-539
ADK	13.	Caruso, A. et al., "Flow cytometric analysis of activation markers on stimulated T cells and their correlation with cell proliferation" (1997) <i>Cytometry</i> 27:71-76
ADK	14.	Correll, P.H. et al., "Production of human glucocerebrosidase in mice after retroviral gene transfer into multipotential hematopoietic progenitor cells" (1989) <i>PNAS USA</i> 86:8912-8916
ADK	15.	Coulie, P.G., "Human tumour antigens recognized by T cells: new perspectives for anti-cancer vaccines?" (1997) <i>Molec. Med. Today</i> 3:261-268
ADK	16.	Culver, K. et al., "Lymphocytes as cellular vehicles for gene therapy in mouse and man" (1991) <i>PNAS USA</i> 88:3155-3159
ADK	17.	Dharanipragada, R. et al., "The absolute configuration of an intermediate in the asymmetric synthesis of unusual amino acids" (1992) <i>Acta. Cryst.</i> C48:1239-1241
ADK	18.	Dharanipragada, R. et al., "Synthetic linear and cyclic glucagon antagonists" (1993) <i>Int. J. Peptide Protein</i>

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449		Docket No. 126881209400		Appl. No. 09/812,238	
INFORMATION DISCLOSURE STATEMENT (use several sheets if necessary)		Applicant(s) Charles A. NICOLETTE			
		Filing Date: March 19, 2001		Group Art Unit: 1644 1654	
		Res. 42(1):68-77			
ADK	19.	DiMaio, J. et al., "Synthesis of chiral piperazin-2-ones as model peptidomimetics" (1989) <i>J. Chem. Soc. Perkin Trans. 1</i> (9):1687-1689			
ADK	20.	Feltkamp, M.C.W. et al., "Competition inhibition of cytotoxic T-lymphocyte (CTL) lysis, a more sensitive method to identify candidate CTL epitopes than induction of antibody-detected MHC class I stabilization" (1995) <i>Immunol. Lett.</i> 47:1-8			
ADK	21.	Ferguson, et al. "Cell-surface anchoring of proteins via glycosyl-phosphatidylinositol structures" (1988) <i>Ann. Rev. Biochem.</i> 57:285-320			
ADK	22.	Fujihashi, K. et al., "Cytokine-specific ELISPOT assay single cell analysis of IL-2, IL-4 and IL-6 producing cells" (1993) <i>J. Immunol. Meth.</i> 160:181-189			
ADK	23.	Garvey D.S. et al., "3,4-disubstituted $\gamma$ -lactam rings as conformationally constrained mimics of peptide derivatives containing aspartic acid or norleucine" (1990) <i>J. Org. Chem.</i> 55(3):936-940			
ADK	24.	Hruby, V.J., "Conformational restrictions of biologically active peptides via amino acid side chain groups" (1982) <i>Life Sciences</i> 31:189-199			
ADK	25.	Hruby, V.J. et al. "Emerging approaches in the molecular design of receptor-selective peptide ligands: conformational, topographical and dynamic considerations" (1990) <i>Biochem J.</i> 268:249-262			
ADK	26.	Isakov, N. et al., "ZAP-70 binding specificity to T cell receptor tyrosine-based activation motifs: The tandem SH2 domains of ZAP-70 bind distinct tyrosine-based activation motifs with varying affinity" (1995) <i>J. Exp. Med.</i> 181:375-380			
ADK	27.	Jones, R.C.F. and G.J. Ward, "Amide bond isosteres: imidazolines in pseudopeptide chemistry" (1988) <i>Tetrahedron Lett.</i> 29(31):3853-3856			
ADK	28.	Kahn, M. and S. Bertenshaw, "The incorporation of $\beta$ -turn prosthetic units into merrifield solid phase peptide synthesis" (1989) <i>Tetrahedron Lett.</i> 30(18):2317-2320			
ADK	29.	Karlsson, S. et al., "Stable gene transfer and tissue-specific expression of a human globin gene using adenoviral vectors" (1986) <i>The EMBO J.</i> 5(9):2377-2385			
ADK	30.	Kawakami, Y. et al., "Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor" (1994) <i>PNAS USA</i> 91(9):3515-3519			
ADK	31.	Kazmierski, W. M. and V.J. Hruby, "Asymmetric synthesis of topographically constrained amino acids: synthesis of the optically pure isomers of $\alpha,\beta$ -dimethyl-phenylalanine and $\alpha,\beta$ -dimethyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid" (1991) <i>Tetrahedron Lett.</i> 32(41):5769-5772			
ADK	32.	Kazmierski, W.M. et al., "Topographic design of peptide neurotransmitters and hormones on stable backbone templates: relation of conformation and dynamics to bioactivity" (1991) <i>J. Am. Chem. Soc.</i> 113:2275-2283			
ADK	33.	Kemp, D.S. and P.E. McNamara, "Conformationally restricted cyclic nonapeptides derived from L-cysteine and LL-3-amino-2-piperidone-6-carboxylic acid (LL-Acp), a potent $\beta$ -turn-inducing dipeptide analogue" (1985) <i>J. Org. Chem.</i> 50:5834-5838			
ADK	34.	Kemp, D.S. and B.R. Bowen, "Conformational analysis of peptide-functionalized diacylaminoepindolidiones $^1\text{H}$ NMR evidence for $\beta$ -sheet formation" (1988) <i>Tetrahedron Lett.</i> 29(40):5081-5082			
ADK	35.	Kemp, D.S. and W.E. Stites, "A convenient preparation of derivatives of 3(S)-amino-10(R)-carboxy-1, 6-diaza-cyclodeca-2, 7-dione The dilactam of L- $\alpha$ , $\gamma$ -diaminobutyric acid and D-glutamic acid: A $\beta$ -turn template" (1988) <i>Tetrahedron Lett.</i> 29(40):5057-5060			
ADK	36.	Kemp, D.S. and T.P. Curran, "(2, 5S, 8S, 11S)-1-acetyl-1, 4-diaza-3-keto-5-carboxy-10-thia-tricyclo-[2.8.0 <sup>4,6</sup> ]-ridecane, 1 the preferred conformation of 1 (1= $\alpha$ temp-OH) and its peptide conjugates $\alpha$ temp-L-(Ala) <sub>n</sub> -OR (n=1 to 4) and $\alpha$ -temp-L-Ala-L-Phe-Lys( $\epsilon$ Boc)-L-Lys( $\epsilon$ -Boc)-NHMe studies of templates for $\alpha$ -helix			
EXAMINER:		DATE CONSIDERED: 8/11/04			
EXAMINER: Initial citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.					



PTO/SB/08 (2/92)

Sheet 3 of 4

RECEIVED  
AUG 14 2001  
TECH CENTER 1600 29th


Form PTO-1449		Docket No. 126881209400	Appl. No. 09/812,238
INFORMATION DISCLOSURE STATEMENT		Applicant(s) Charles A. NICOLETTE	
(use several sheets if necessary)		Filing Date: March 19, 2001	Group Art Unit: <del>4814</del> 1654
		formation" (1988) <i>Tetrahedron Lett.</i> 29(39):4935-4938	
AK	37.	Kemp, D.S. and J.S. Carter, "Amino acid derivatives that stabilize secondary structures of polypeptides. 4. Practical synthesis of 4-(alkylamino)-3-cyano-6-azabicyclo[3.2.1]oct-3-enes (ben derivatives) as $\gamma$ -turn templates" (1989) <i>J. Org. Chem.</i> 54:109-115	
AK	38.	McGrory, W.J. et al., "Short communications: A simple technique for the rescue of early region I mutation into infectious human adenovirus type 5" (1988) <i>Virology</i> 163:614-617	
AK	39.	Merrifield, R.B., "New approaches to the chemical synthesis of peptides" (1967) <i>Recent Progress in Hormone Res.</i> 23:451-482	
AK	40.	Miyake, A. et al., "Synthesis and angiotensin converting enzyme inhibitory activity of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives" (1984) <i>J. Takeda Res. Labs.</i> 43(3/4):53-76	
AK	41.	Mosier, D.E. et al., "Resistance to human immunodeficiency virus 1 infection of SCID mice reconstituted with peripheral blood leukocytes from donors vaccinated with vaccinia gp160 and recombinant gp160" (1993) <i>PNAS. USA</i> 90:2443-2447	
AK	42.	Muzyczka, "Use of adeno-associated virus as a general transduction vector for mammalian cells" (1992) <i>Curr. Top. Microbiol. Immunol.</i> 158:97-129	
AK	43.	Nagai, U. and K. Sato, "Synthesis of a bicyclic dipeptide with the shape of $\beta$ -turn central part" (1985) <i>Tetrahedron Lett.</i> 26(5):647-650	
AK	44.	Nair, S. et al., "Soluble proteins delivered to dendritic cells via pH-sensitive liposomes induce primary cytotoxic T lymphocyte responses in vitro" (1992) <i>J. Exp. Med.</i> 175:609-612	
AK	45.	Olson, G.L. et al., "Design and synthesis of a protein $\beta$ -turn mimetic" (1990) <i>J. Am. Chem. Soc.</i> 112:323-333	
AK	46.	Paglia, P. et al., "Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo" (1996) <i>J. Exp. Med.</i> 183:317-322	
AK	47.	Pardoll, D.M., "Cancer vaccines" (1998) <i>Nature Med.</i> 4(5 Suppl.):525-531	
AK	48.	Parker, et al., "Sequence motifs important for peptide binding to the human MHC class I molecule, HLA-A2" (1992) <i>J. Immunol.</i> 149(11):3580-3587	
AK	49.	Parker, K.C. et al. (1995) "Peptide Binding to MHC Class I Molecules: Implications for Antigenic Peptide Prediction" <i>Immunol. Res.</i> 14:34-57.	
AK	50.	Parkhurst, M.R. et al., "Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues" (1996) <i>J. Immunol.</i> 157:2539-2548	
AK	51.	al-Ramadi, B.K. et al., "Lack of strict correlation of functional sensitization with the apparent affinity of MHC/peptide complexes for the TCR" (1992) <i>J. Immunol.</i> 155(2):662-673	
AK	52.	Rill, D.R. et al., "An approach for the analysis of relapse and marrow reconstitution after autologous marrow transplantation using retrovirus-mediated gene transfer" (1992) <i>Blood</i> 79(10):2694-2700	
AK	53.	Rouse, R.J.D. et al., "Induction in vitro of primary cytotoxic T-lymphocyte responses with DNA encoding herpes simplex virus proteins" (1994) <i>J. Virol.</i> 68(9):5685-5689	
AK	54.	Salazar, E. et al., "Agonist peptide from a cytotoxic T-lymphocyte epitope of human carcinoembryonic antigen stimulates production of TC1-type cytokines and increases tyrosine phosphorylation more efficiently than cognate peptide" (2000) <i>Int. J. Cancer</i> 85:829-838	
AK	55.	Samanen, J. et al., "5,5-dimethylthiazolidine-4-carboxylic acid (DTC) as a proline analog with restricted conformation" (1990) <i>Int. J. Peptide Protein Res.</i> 35:501-509	
AK	56.	Schlesinger, S. and T.W. Dubensky, Jr., "Alphavirus vectors for gene expression and vaccines" (1999) <i>Curr Opin Biotechnol.</i> 10(5):434-439	
AK	57.	Sette, A. et al., "The relationship between class I binding affinity and immunogenicity of potential cytotoxic	

Abstract only

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.



PTO/SB/08 (2/92)

Sheet 4 of 4

RECEIVED

AUG 14 2001  
FBI CENTER 1600/2900

Form PTO-1449		Docket No. 126881209400	Appl. No. 09/812,238
INFORMATION DISCLOSURE STATEMENT		Applicant(s) Charles A. NICOLETTE	
(use several sheets if necessary)		Filing Date: March 19, 2001	Group Art Unit: 1614 1654
		T cell epitopes" (1994) <i>J. Immunol.</i> <b>153</b> (12):5586-5592	
AM	58.	Shirai, M. et al., "CTL responses of HLA-A2.1-transgenic mice specific for hepatitis C viral peptides predict epitopes for CTL of humans carrying HLA-A2.1" (1995) <i>J. Immunol.</i> <b>154</b> :2733-2742	
AM	59.	Stuber, G. et al., "HLA-A0201 and HLA-B7 binding peptides in the EBV-encoded EBNA-1, EBNA-2 and BZLF-1 proteins detected in the MHC class 1 stabilization assay. Low proportion of binding motifs for several HLA class 1 alleles in EBNA-1" (1995) <i>Int. Immunol.</i> <b>7</b> (4):653-663	
AM	60.	Tan, L. et al., "An improved assembly assay for peptide binding to HLA-B*2705 and H-2K*class I MHC molecules" (1997) <i>J. Immunol. Meth.</i> <b>209</b> (1):25-36	
AM	61.	Tanguay, S. and J.J. Killian, "Direct comparison of ELISPOT and ELISA-based assays for detection of individual cytokine-secreting cells" (1994) <i>Lymphokine Cytokine Res.</i> <b>13</b> (4):259-263	
AM	62.	Valmori, D. et al., "Induction of potent antitumor CTL responses by recombinant vaccinia encoding a melan-A peptide analogue" (2000) <i>J. Immunol.</i> <b>164</b> (2):1125-1131	
AM	63.	van der Burg, S.H. et al., "Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability" (1996) <i>J. Immunol.</i> <b>156</b> :3308-3314	
AM	64.	Ware, C.F. et al., "Recognition of HLA-A2 mutant and variant target cells by an HLA-A2 allospecific human cytotoxic T lymphocyte line" (1983) <i>J. Immunol.</i> <b>131</b> (3):1312-1317	
AM	65.	Wilchek, M. and E.A. Bayer, "The avidin-biotin complex in bioanalytical applications" (1988) <i>Anal. Biochem.</i> <b>171</b> :1-32	
AM	66.	Ying, H. et al., "Cancer therapy using a self-replicating RNA vaccine" (1999) <i>Nat. Med.</i> <b>5</b> (7):823-827	
AM	67.	Zabrocki, J. et al., "Conformational mimicry. 1. 1,5-disubstituted tetrazole ring as a surrogate for the cis amide bond" (1988) <i>J. Am. Chem. Sci.</i> <b>110</b> :5875-5880	
AM	68.	Zechel, C. et al., "Synthetic glucagon antagonists and partial agonists" (1991) <i>Int. J. Pep. Protein Res.</i> <b>38</b> (2):131-138	
AM	69.	Zuegel, et al., "Termination of peripheral tolerance to a T cell epitope by heteroclitic antigen analogues" (1998) <i>J. Immunol.</i> <b>161</b> (4):1705-1709	
AM	70.	Zweerink, H.J. et al., "Presentation of endogenous peptides to MHC class I-restricted cytotoxic T lymphocytes in transport deletion mutant T2 cells" (1993) <i>J. Immunol.</i> <b>150</b> (5):1763-1771	

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	





Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-PTO

Complete if Known

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

1

Application Number

09/812,238

Filing Date

March 19, 2000

First Named Inventor

Charles A NICOLETTE

Art Unit

1654 1614

Examiner Name

Not Yet Assigned

Attorney Docket Number

GZ 2094.00

TECH CENTER 1601/2900

AUG 07 2002

RECEIVED

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
ADK	1	US-5,695,937	12/9/97	Kinzler et al.	
ADK	2	US-5,844,075	12/1/98	Kawakami et al.	
ADK	3	US-5,869,445	2/9/99	Cheever, et al.	
ADK	4	US-6,028,059	2/22/00	Curiel, et al.	

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>3</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
ADK	5	FR 2,757,169		Institute Nat'l de la Sante et de la Recherche Medical InsermEtabliss Public a Caract Scient et Tech		
ADK	6	WO 97/35035		Genzyme Corp.		
ADK	7	WO 99/02183		CTL Immunotherapies Corp.		
ADK	8	WO 00/20457		Genzyme Corp.		


Examiner's  
SignatureDate  
Considered

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

+ Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.





PTO/SB/08 (2/92)  
Sheet 1 of 1  
**RECEIVED**  
FEB 04 2002  
TECH CENTER 1600/2900

Form PTO-1449	Docket No. GZ 2094.00	Appl. No. 09/812,238
INFORMATION DISCLOSURE STATEMENT	Applicant(s) Charles A. NICOLETTE	
(use several sheets if necessary)	Filing Date: March 19, 2001	Group Art Unit: Not Yet Assigned 1654

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date (if appropriate)

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Translation YES NO
AAE	1.	08/23/95	0 668 350 A1	Akzo Nobel N.V.			

OTHER DOCUMENTS

(including author, title, date, pertinent pages, etc.)

Examiner Initials	Ref. No.	Title
AM	2.	Parkhurst, M., et al. "Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues" <i>The J. Immunology</i> 157:2539-2548 (1996).
AM	3.	Bakker, A.B. H., et al. "Analogues of CTS epitopes with improved MHC class-I binding capacity elicit anti-melanoma CTL recognizing the wild-type epitope" <i>Int. J. Cancer</i> 70:302-309 (1997).

EXAMINER:	DATE CONSIDERED: 8/14/01
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.  
Substitute for form 1449B-PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	09/812,238
Filing Date	March 19, 2001
First Named Inventor	Charles A. NICOLETTE
Art Unit	1614-1654
Examiner Name	Not Yet Assigned
Attorney Docket Number	GZ 2094.00

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published
1	ALEXANDER-MILLER, M. et al. "Selective expansion of high-or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy" <i>PNAS USA</i> (1996) 93(9):4102-4107.
2	BLOOM, M.B. et al. "Identification of tyrosine-related protein 2 as a tumor rejection antigen for the melanoma" <i>J. Exp. Med.</i> (1997). 185(3):45
3	BORCHARDT, A. et al., "Small molecule-dependent genetic selection in stochastic nanodroplets as a means of detecting protein-ligand interactions on a large scale" <i>Chem. Biol.</i> (1997) 4(12):961-968
4	BOUCHARD, B. et al., "Molecular characterization of a human tyrosinase-related-protein-2 cDNA. Patterns of expression in melanocytic cells" <i>Eur. J. Biochem</i> (1994). 219(1-2):127-134
5	COLACO, C.A.L.S. "Why are dendritic cells central to cancer immunotherapy?" <i>Mol. Med.</i> (January 1999) <i>Today</i> :14-17 <i>Mol Med Today</i>
6	FISK, B. et al. "Changes in an HER-2 peptide upregulating HLA-A2 expression affect both conformational epitopes and CTL recognition: Implications for Optimization of antigen presentation and tumor-specific CTL induction" <i>Immunol.</i> (1996) 18(4):197-209 <i>J. Immunol.</i>
7	FORBES, J.F. "The incidence of breast cancer: The global burden, public health considerations" <i>Seminars in Oncology</i> (1997) 24(1), Suppl. 1, pp. S1-20-S1-35
8	GISH, W. and D.J. STATES "Identification of protein coding regions by database similarity search" <i>Nature Genetics</i> (1993) 3:266-273
9	GREENLEE, R.T. et al. "Cancer Statistics, 2001". <i>CA Cancer J Clin</i> (2001) 51(1):15-36
10	KAWAKAMI, Y. et al., "Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with <i>in vivo</i> tumor rejection" <i>PNAS USA</i> (1994) 91:6458-6462
11	KUHNS, J.J. et al. "Poor Binding of a HER-2/neu Eptope (GP2) to HLA-A2.1 is due to a lack of interactions with the center of the peptide" <i>J. Biol. Chem.</i> (1999) 274:36422-36427
12	LINDAUER, M. et al., "The molecular basis of cancer immunotherapy by cytotoxic T lymphocytes" <i>J. Mol. Med.</i> (1998) 76:32-47
13	LOCKHART, D.J. and E.A. WINZELER "Genomics, gene expression and DNA arrays" <i>Nature</i> (2000) 405:827-836
14	RIES, L.A.G. et al. "The annual report to the nation on the status of cancer, 1973-1997, with a special section on colorectal cancer" <i>Cancer</i> (2000) 88(10):2398-2424
15	RONGEUN, Y. et al. "Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas" <i>J. Immunol.</i> (1999) 163:1037-1044
16	ROSENBERG, S.A. et al., "Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma" <i>Nature Med.</i> (1998) 4(3):321-327
17	SALGALLER, M.L. et al., "Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated <i>in vitro</i> with synthetic peptides" <i>Cancer Res.</i> (1995) 55:4972-4979
18	SCHENA, M. et al., "Parallel human genome analysis: Microarray-based expression monitoring of 1000 genes" <i>PNAS USA</i> (1996) 93:10614-10619
19	SHEPHERD, N.S. et al., "Preparation and screening of an arrayed human genomic library generated with the P1 cloning system" <i>PNAS USA</i> (1994) 91:2629-2633
20	SHIKE, M. et al. "Primary prevention of colorectal cancer" <i>Bulletin of the World Health Organization</i> (1990) 68(3):377-385
21	SRINIVAS, P.R. et al. "Proteomics in Early Detection of Cancer" <i>Clin. Chem.</i> (2001) 47(10):1901-1911

RECEIVED

AUG 07 2002

TECH CENTER 1600 2900

8/19/04

